Objective: The purpose of this study was to evaluate the demographic characteristics and outcomes of neonates who were admitted to a neonatal intensive care unit and treated with inhaled nitric oxide (iNO) during the years 2000-08. The goal of studying this group of neonates was to evaluate how iNO use has evolved in infants and to estimate the frequency of off-label use of this drug in this population.
Introduction
Inhaled nitric oxide was approved for use in neonates in December 1999. The Food and Drug Administration label for inhaled nitric oxide (iNO) states that 'INOmax, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.' (http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id ¼ 11080) In a meta-analysis of clinical studies involving term and late preterm neonates, Finer and Barrington 1 concluded that 'based on the evidence presently available, including the neurodevelopmental and general medical outcome information, near-term and term infants with hypoxic respiratory failure unresponsive to other therapy, excluding infants with diaphragmatic hernia, should have a trial of inhaled nitric oxide.' 1 The use of iNO in more premature (<34 weeks) infants has generally focused on two high-risk groups; those with severe acute respiratory distress 2, 3 and those at high risk of developing bronchopulmonary dysplasia (BPD). [4] [5] [6] In a recent meta-analysis of the published clinical studies involving preterm infants, Barrington and Finer 7 concluded that 'y iNO should not be routinely used for preterm infants as a rescue therapy in cases of hypoxic respiratory failure. In contrast, the early routine use of iNO in ventilated preterm infants who are not severely ill, but nevertheless are at risk for serious brain injury or bronchopulmonary dysplasia, holds promise.' 7 The purpose of our study was to determine whether changes in practice are consistent with the suggestions of these two meta-analyses; more specifically, our goal was to evaluate how the off-label use of iNO has changed since its approval in late 1999.
Methods

Study type
Retrospective review of the Pediatrix Clinical Data Warehouse de-identified data set.
Patient population
Neonates were included in our study sample if they required admission to a neonatal intensive care unit. This study included patients who were discharged between 1 January 2000 and 31 December 2008.
Data set
Pediatrix Medical Group provides intensive care services in 244 hospitals in 32 states and Puerto Rico. Nine (3.7%) centers provide extracorporeal membrane oxygenation. The proportion of units reporting use of any iNO increased from 39% in 2000 to 42% in 2008.
Pediatrix Medical Group health care professionals (doctors and nurse practitioners) providing care to neonates admitted for intensive care use a proprietary software system to generate clinical admission, discharge and daily progress notes. These data are stored in a consolidated data set and then de-identified for quality improvement and research. Using the de-identified data set, from which several other observations have been reported, [8] [9] [10] we performed a retrospective case series review of neonates with a report of having been treated with iNO. Cases were identified by searching the respiratory support and medications table in our database for the term 'nitric oxide.' Neonates who died in the delivery room or those who were not admitted for neonatal intensive care were not included in the data set.
Clinicians providing care to patients interact with the patients' data on a daily basis, in order to generate progress notes and to provide billing information. Each day's notes are stored with diagnoses. The local data are consolidated within the Pediatrix Medical Group data warehouse, de-identified, made compliant with Health Insurance Portability and Accountability Act of 1996 regulations. Data are also configured into tables that can be joined and queried for statistical analyses. The Western Institutional Review Board and the Greenville Memorial Hospital, Greenville, SC, institutional review boards approved our research with the de-identified data set.
Our analytical approach to these data was descriptive in nature. Specific database tables within the data warehouse used for this analysis were 'patients,' 'medications,' 'admissions' and 'diagnoses.' Data on estimated gestational age represented the best estimates from both obstetrical data and neonatal examination findings. All patients with a report of having been treated with iNO in the medications table were reviewed. In the diagnosis table, we searched for congenital diaphragmatic hernia and congenital heart diseases (congenital heart disease, cyanotic heart disease, transposition, tetralogy, total anomalies pulmonary venous return, Ebstein's Anomaly, tricuspid atresia, truncus arteriosus or hypoplastic left heart, coarctation of the aorta and complex heart disease). We estimated the total numbers of days of iNO use in each patient by subtracting the age at the start of therapy from the age at the end of therapy for the first course of therapy. We did not capture second courses of therapy. The total number of days of use of iNO was calculated by summing these values for each year.
Differences in the demographic characteristics of patients within each time group were analyzed by comparing the three population samples (2000-02; 2003-05; 2006-08) in two estimated gestational age groups (X34 and <34 weeks estimated gestational age) ( Tables 1 and 2 , respectively). Continuous variables for example, estimated gestational age and birth weight) were evaluated with analysis of variance and post hoc analysis to identify specific subgroup differences. Categorical variables (for example, race and gender) were evaluated with two-tailed w 2 -tests. Nonparametric data were assessed with Kruskal-Wallis analysis of variance. We used the linear trend test and the Cochran-Armitage trend test to evaluate time-related changes. All statistical analyses were performed using JMP 7 (SAS Institute, Cary, NC, USA). Of infants who were treated with iNO (n ¼ 4316), the proportion of infants <34 weeks (off-label use) has increased from 31 of 154 (20%) neonates in 2000 to 399 of 918 (43%) neonates for the years 2006-08. In 2008, we estimated that iNO was used for a total of 4665 days and 2498 (53.5%) of these days of iNO treatment were in neonates who were <34 weeks.
Results
There
Late preterm and term infants (on-label use)
In neonates who were born X34 weeks, there were no significant time-related changes in the median gestational age, birth weight, or in the proportion that were male, that were outborn, or that had congenital diaphragmatic hernia or congenital heart disease ( Table 1) . The age at which iNO was started and the duration of iNO treatment also did not change significantly. Over the time periods studied, there was a significant increase in the number of infants that had been delivered by cesarean section and more of the neonates were treated with surfactant and/or high frequency ventilation (HFV). The proportion of iNO-treated neonates with pulmonary hypertension, congenital diaphragmatic hernia and heart disease remained relative constant, whereas the proportion of patients with a report of respiratory distress syndrome increased and the proportion with meconium aspiration decreased. The use of vasopressor decreased slightly and mortality rate remained relatively constant at 11%.
Neonates <34 weeks estimated gestational age (off-label use)
In neonates who were born <34 weeks, there was no significant time-related changes in the proportion that were male, that were outborn, that were born by cesarean section or that had congenital diaphragmatic hernia or congenital heart disease ( Table 2) . Over the time periods studied, there was a significant decrease in the median gestational age and birth weight of infants treated with iNO. In more recent years, the neonates born <34 weeks' gestational age were treated for longer periods of time but the median age at initiation of iNO did not change and remained <2 days after birth. The proportion of neonates started on therapy after 7 days of life and the proportion of neonates treated for >7 days increased (Table 2 ). There was no significant time-related changes in the proportion treated with surfactant, but in later years, more of these premature infants were on HFV at the time iNO was started. The proportion of iNO-treated neonates with pulmonary hypertension, respiratory distress syndrome, congenital diaphragmatic hernia and heart disease remained relative constant for neonates born <34 weeks. For neonates treated with iNO, the mortality rate in neonates born <34 weeks was significantly higher than those born at >34 weeks, but there was no significant change over time in these premature infants and the mortality ranged from 31 to 37%.
Discussion
The characteristics of infants treated with iNO has changed significantly over time following the Food and Drug Administration approval of the drug. The major shift has been in the significant increased off-label use of iNO in premature neonates. Several large clinical trials have evaluated the safety and efficacy of iNO therapy in premature newborns. [3] [4] [5] [6] [7] 11 All these studies were randomized, controlled and masked, but there are important differences in patient population, disease severity, Use of iNO in the NICU RH Clark et al and dose and duration of therapy that offer insight into the premature neonates most likely to benefit from iNO treatment. 11 Schreiber et al. 6 studied 207 neonates in an early intervention trial (median age at randomization B13 h of age) and found a reduction in the incidence of BPD and death by 24% in the iNO group. These authors also reported that iNO was associated with a decrease in intracranial hemorrhage and periventricular leukomalacia, and iNO treatment resulted in improved neurodevelopmental outcome. 12 These benefits seemed to occur predominantly in the subset of newborns with relatively mild respiratory failure (oxygenation index <7).
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Van Meurs et al.
3 studied 420 very low birth weight newborns with severe respiratory failure (mean oxygenation index of 23±17) and found no difference in the incidence of death/BPD between the iNO and control groups. However, in a post hoc analysis of newborns weighing <1000 g, Van Meurs et al. 3 found an increased risk of intracranial hemorrhage and periventricular leukomalacia (43% iNO vs 33% control). In the Van Meurs study population, the initial severity of respiratory failure was much worse than the degree of respiratory failure of neonates in the Schreiber et al. 6 study population. The mean oxygenation index in the Van Meurs study was 23 ± 17 compared with a median oxygenation index of B7 in the Schreiber study. The difference in the results reported by the Van Meurs and Schreiber studies suggests that the severity of respiratory failure may influence the safety and efficacy of iNO in premature neonates. 11 The two largest randomized, controlled and masked trials of iNO treatment in premature newborns were reported by Ballard et al., 4, 13 and Kinsella et al. 5 Ballard randomized 582 premature newborns with birth weights of 500 to 1250 g who required ventilatory support between 7 and 21 days of age. 4, 13, 14 Infants were treated with study gas for a minimum of 24 days and the incidence of survival without BPD was better in the iNO treatment group (43.9%) compared with controls (36.8%). Ballard et al. 4 reported that iNO treatment produce the most benefit in preterm infants who were started on treatment between the ages of 7 and 14 days but not in the group of infants between the ages of 15 and 21 days. In the Kinsella trial, 5 793 premature newborns with birth weights of 500 to 1250 g and requiring mechanical ventilation in the first 48 h of life were randomized to treatment with 5 p.p.m. iNO or placebo gas and were treated for 21 days or until the endotracheal tube was removed. Overall, there was no difference in the incidence of death or BPD between groups in the Kinsella study.
On the basis of these prospective clinical studies, the evidence would suggest that there might be a targeted role for the use of iNO in neonates with persistent need (7 to 14 days after birth) for assisted ventilation. 4 There is no evidence that the short-term (<7 days) use of iNO for the 'rescue' of extremely preterm infant with severe respiratory failure is helpful. 3, 7 And yet our data indicate that this latter group represents the population in which the biggest increase in the use of iNO has occurred. There has been very little change in the clinical characteristics of iNO-treated neonates who are X34 or more weeks' gestational age. In contrast, neonates <34 weeks who were treated with iNO were smaller and more immature in recent years. In addition, premature infants treated with iNO seemed to have more severe lung disease (more often were on HFV). The critical degree of illness in preterm study cohort is highlighted by the fact that over 60% were on HFV at start of iNO and 30% of the preterm neonates treated with iNO died. In addition, the portion of the preterm cohort on HFV increased with time as did mortality. These changes suggest a shift toward treatment of less recoverable preterm neonates. More than 50% of the preterm neonates treated with iNO were started on treatment during the first 3 days (>50%), similar to the approach reported by Van Meurs et al. 3 Only a small proportion (<15%) of the premature neonates in our study cohort were started on treatment between 7 and 14 days. The duration of therapy for the majority (>70%) of treated premature neonates was <7 days; a much shorter duration than that reported by Kinsella et al. 5 or Ballard et al.
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Conclusion
The use of iNO has increased over the past 9 years and this increase is mostly due to off-label use in premature infants. Clinical trials involving preterm infants have not demonstrated a survival advantage for preterm neonates treated with iNO. 15 A new therapy has crept into general clinical practice, its off-label use has expanded over time and the patterns of use do not seem to follow the best evidence from the published clinical trials. Similar changes are evident in the Vermont Oxford Network Expanded Database Summary Reports 16 ( Figure 40 ). On the basis of the current evidence, the increased use of 'rescue' iNO in critically ill, preterm neonates is not justified and only serves to increase healthcare cost without the offsetting advantage of improving short-or long-term outcomes. Targeted clinical trials to test the safety, efficacy and cost benefits of iNO use in preterm infants are still needed. Without them, we may do more harm than good.
